Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Adverse drug events due to drug-drug interactions can be prevented by avoiding concomitant use of causative drugs; therefore, it is important to understand drug combinations that cause drug-drug interactions. Although many attempts to identify drug-drug interactions from real-world databases such as spontaneous reporting systems have been performed, little is known about drug-drug interactions caused by three or more drugs in polypharmacy, i.e., multiple drug-drug interactions. Therefore, we attempted to detect multiple drug-drug interactions using decision tree analysis using the Japanese Adverse Drug Event Report (JADER) database, a Japanese spontaneous reporting system. First, we used decision tree analysis to detect drug combinations that increase the risk of rhabdomyolysis in cases registered in the JADER database that used six statins. Next, the risk of three or more drug combinations that significantly increased the risk of rhabdomyolysis was validated with experiments in rats. The analysis identified a multiple drug-drug interaction signal only for pitavastatin. The reporting rate of rhabdomyolysis for pitavastatin in the JADER database was 0.09, and it increased to 0.16 in combination with allopurinol. Furthermore, the rate was even higher (0.40) in combination with valsartan. Additionally, necrosis of leg muscles was observed in some rats simultaneously treated with these three drugs, and their creatine kinase and myoglobin levels were elevated. The combination of pitavastatin, allopurinol, and valsartan should be treated with caution as a multiple drug-drug interaction. Since multiple drug-drug interactions were detected with decision tree analysis and the increased risk was verified in animal experiments, decision tree analysis is considered to be an effective method for detecting multiple drug-drug interactions.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9608045PMC
http://dx.doi.org/10.7150/ijms.76139DOI Listing

Publication Analysis

Top Keywords

drug-drug interactions
36
multiple drug-drug
28
jader database
16
decision tree
16
tree analysis
16
adverse drug
12
drug combinations
12
drug-drug
11
interactions
9
japanese adverse
8

Similar Publications

The aim of this Phase 1, multicentre, open-label study was to evaluate the safety, tolerability and pharmacokinetics (PK) of abemaciclib administered at global recommended Phase 2 dose (RP2D) of 200 mg twice daily, combined with standard doses of abiraterone and prednisolone, in Japanese patients with metastatic castration-resistant prostate cancer (mCRPC). Dose-limiting toxicities (DLTs) were assessed for 28 days post-first dose. Six patients were treated, and all experienced at least one treatment-emergent adverse event (TEAE), mostly low grade; no Grade 4 or 5 TEAEs occurred.

View Article and Find Full Text PDF

Preface to DMR drug-drug interactions special issue.

Drug Metab Rev

August 2025

Pharmacokinetics, Dynamics, Metabolism and Bioanalytics, Merck & Co., Inc, Boston, MA, USA.

View Article and Find Full Text PDF

Background: The COVID-19 antiviral Nirmatrelvir/Ritonavir (Paxlovid, N/R) was approved for use in Canada in January 2022, with the Government of Canada assuming a procurement role and provinces, territories, and federal departments implementing usage within their respective healthcare systems. The objective of this analysis is to describe how N/R was implemented across various jurisdictions in the first six months after it was available for use and identify promising implementation practices.

Methods: Fourteen semi-structured discussions in small group settings were conducted with jurisdictional representatives involved in the implementation of N/R.

View Article and Find Full Text PDF

Motivation: The increasing demand for effective drug combinations has made drug-drug interaction prediction a critical task in modern pharmacology. While most existing research focuses on small-molecule drugs, the role of biotech drugs in complex disease treatments remains relatively unexplored. Biotech drugs, derived from biological sources, have unique molecular structures that differ significantly from those of small molecules, making their interactions more challenging to predict.

View Article and Find Full Text PDF

Background: Membrane transport proteins are critical determinants of systemic and intracellular drug levels, thereby contributing substantially to drug response and/or adverse drug reactions. Therefore, the U.S.

View Article and Find Full Text PDF